Leqembi Data Confirms Effect on Alzheimer’s Protofibrils
Eisai and Biogen reported new cerebrospinal fluid data at CTAD showing that lecanemab’s binding to amyloid beta protofibrils can...
eClinical Tech News
Parkinson’s Drug Crexont® Shows Promising Phase 4 Results
Amneal reported positive interim results from its ongoing Phase 4 ELEVATE-PD switch study, showing that CREXONT (carbidopa/levodopa extended-release) improved...
Positive Phase 3 VALIANT Results for Empaveli Published
Apellis has secured a decisive evidence win for Empaveli (pegcetacoplan) in rare renal disease: the New England Journal of...
Amicus Therapeutics Q3 2025 Financial Results Announced
Amicus Therapeutics reported third-quarter 2025 revenue of $169.1 million, up 17% at constant exchange rates, and delivered GAAP net...
ADMA Biologics Delivers Complete Q3 2025 Financial Results
ADMA Biologics reported third quarter 2025 revenue of $134.2 million, up 12% year over year, with GAAP net income...
EyePoint Q3 2025 Financial Results & Corporate Highlights
EyePoint Pharmaceuticals has fully enrolled its two Phase 3 trials in wet age-related macular degeneration (LUGANO and LUCIA), initiated...
Moonlake Reports Q3 Financials, New Sonelokimab Trial Data
MoonLake Immunotherapeutics reported third-quarter 2025 results and a cascade of clinical updates that set up sonelokimab for a pivotal...
Inotiv Reports Q4 and Full-Year 2025 Financial Results
Inotiv reported fourth-quarter fiscal 2025 revenue of $138.1 million, up 5.9% year over year, and full-year revenue of $513.0...
BioCryst’s Successful Astria Acquisition Gets Early Approval
BioCryst Pharmaceuticals received early termination of the Hart-Scott-Rodino waiting period for its proposed acquisition of Astria Therapeutics, clearing a...
Catalyst Pharmaceuticals Reports Q3 2025 Financial Results
Catalyst Pharmaceuticals posted third-quarter 2025 revenue of $148.4 million, up 17% year over year, and raised full-year guidance to...